Stifel Nicolaus reiterated its Buy rating on InterMune ITMN but lowered its price target from $22 to $19.
Stifel Nicolaus commented, "Our 12-month target price of $19/share (previously $22/share) is based on the midpoint of our P/E multiple (25x our FY17E fully-taxed/diluted non-GAAP EPS estimate of $1.83 discounted at 20%-25%/year) and DCF-based methodologies. Our current estimates/valuation continue to assume Esbriet sales in Europe-only (but include U.S. development costs) and our probability-adjusted U.S. sales estimates (peak sales of >$1 billion) generate an additional $30+ per share of DCF-based optionality that remains excluded from our model."
InterMune closed at $10.46 on Thursday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in